ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: PP16

Peer Health Coaches Help Scleroderma Patients Cope with Isolation
Abstract Number: 1964

Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization
Abstract Number: 0867

Pentosan Polysulfate Sodium, a Glycosaminoglycan Mimetic Demonstrates Durable Effects on Pain, Function and Joint Structure in Canine Naturally Occurring Osteoarthritis
Abstract Number: 1803

Perceived Dignity in Patients with Rheumatic Diseases: An Unrecognized Source of Emotional Distress
Abstract Number: 2064

Perceptions of Rheumatology Fellows on Mentorship Quality After Implementation of a Formalized Mentorship Program
Abstract Number: 1872

Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Abstract Number: 0096

Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories
Abstract Number: 0581

Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases
Abstract Number: 0580

Performance of Conventional Cardiovascular Risk Scores in Identifying Subclinical Atherosclerosis in Systemic Lupus Erythematosus
Abstract Number: 1880

Performance of Machine Learning Algorithms in Discriminating Spondyloarthritis Features on Magnetic Resonance Imaging: A Systematic Review and Meta-analysis
Abstract Number: 0848

Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients
Abstract Number: 1515

Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis
Abstract Number: 2126

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity
Abstract Number: 1867

Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography
Abstract Number: 0850

Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].